Author's response to reviews

**Title:** Comparison of Prasugrel and Clopidogrel Reloading on High Platelet Reactivity in Clopidogrel-loaded Patients Undergoing Percutaneous Coronary Intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial

**Authors:**

Dong Hyun Lee (insulin@empal.com)
Moo Hyun Kim (kimmh@dau.ac.kr)
Tae-Ho Park (thpark65@dau.ac.kr)
Jong Sung Park (thinkmed@naver.com)
Kyungil Park (sotier@dau.ac.kr)
Hong-Zhe Zhang (zhanghongzhe@hanmail.net)
Jeong-Min Seo (nunikuh@hanmail.net)
Michael S Lee (MSLee@mednet.ucla.edu)

**Version:** 4  **Date:** 4 February 2013

**Author's response to reviews:** see over
February 4th, 2013

Dear Editor,

We highly appreciate the detailed and comprehensive comments and apologize for the inconvenience that resulted from our ambiguity. We understand our oversights and catch the meaning of your valuable feedback. Your comment was well received by all authors and the third revision has been completed accordingly. We believe this revision has improved the overall structure and hope that the revised manuscript meets the requirements of your journal.

Thank you again for your valuable review and consideration.

Sincerely yours,

Moo-Hyun Kim, MD, FACC
Professor, Corresponding author
Department of Cardiology, College of Medicine, Dong-A University Hospital
3-1, Dongdaeshin-Dong, Seo-Gu, Busan, Republic of Korea, 602-715
Tel: +82-51-240-2976, Fax: +82-51-255-2177
kimmh@dau.ac.kr
Title: Comparison of Prasugrel and Clopidogrel Reloading on High Platelet Reactivity in Clopidogrel-loaded Patients Undergoing Percutaneous Coronary Intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial

Version: 3

Editor's comments:

"Thank you very much for revising and improving the manuscript. Unfortunately, I'm still confused about the simultaneous use of 'open-label' and 'blind'. Although you don't specify the way you achieve such masking, you numerate who is blinded on page 4. But please note that this is completely in opposition to the term 'open label', which is repeated 2 times. Please, consider deleting either the sentences about who is blinded or 'open label'. In the last case, please consider specifying the method to mask the intervention 'to physicians allocated to administer the drugs' (Are interventions similar enough to avoid double dummy?)."

- We apologize again for the oversights. We would like to confirm that the study PRAISE-HPR is an open-label study. Data will be analyzed by personnel who are not informed of particular patient treatment allocations (as 'blind'). We have corrected the sentences which caused unintended misunderstandings.